BioCentury's eighth annual
review of the financing needs for European biotech shows a record number of
biopharma companies have reached the clinic and beyond.
While in total these private
and public biotechs also have registered the largest amount of money needed to
finance the next three years of runway - €3.5 billion ($4.8
billion) - the individual companies are showing a continued trend toward
burning less money to advance their programs.